Need Help? Chat Now With a Live Representative!

ARG Optimizes Clinical Studies with Veeva Vault eTMF & Veeva Vault CTMS

ARG Optimizes Clinical Studies with Veeva Vault eTMF & Veeva Vault CTMS

ARG Optimizes Clinical Studies with Veeva Vault eTMF & Veeva Vault CTMS

June 17, 2020

ARG and Veeva recently collaborated on a case study that focuses on improving trial execution and visibility with Veeva Vault eTMF and Veeva Vault CTMS.
Key contributions from ARG team members:

  • Hunter Walker, chief technology officer: "Our goal with automation is to free our resources to tackle challenging tasks and solve bigger problems, not reduce headcount.”
  • David Tyson, clinical operations manager: “Now, when sponsors ask us to add different types of documentation at the end of studies, we can easily accommodate the requests with minimal effort.”
  • Jen Stanislawski, quality assurance manager:“We use Vault reports to perform pre-inspection quality control (QC). The ability to generate a report showing all unblinded study documents enables us to quickly review content and minimize stress.”

Implementation best practices:

  1. Decide on process changes before implementation. Evaluate current processes and decide if template updates are needed (e.g., amend trip report templates before study go-live to eliminate change controls later).
  2. Align with the clinical operations team. Collaborate early and often to assist with change management. Provide proper training before the first study launches in Vault to ensure a successful rollout.
  3. Account for validation timelines. Build adequate time into the project plan for validation script creation, execution, and summary reports.
  4. Institute a site naming convention. Follow a site naming convention for all studies to assist with reporting and programmatically control the naming of documents via the metadata fields within the document.

Please read the entire case study here.
 

ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

CHARLOTTESVILLE, VIRGINIA – ARG (Atlantic Research Group) proudly announces its ongoing collaboration with Humacyte, a leading biotechnology company, on the […]

February 23, 2024
Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

In 2014, ARG began working with Humacyte on their Human Acellular Vessel (HAV) interposition graft program, which included three separate […]

February 7, 2024
Curiosity and Communication Drive ARG’s Partners Towards Success

Curiosity and Communication Drive ARG’s Partners Towards Success

After leaving her role as a small-town pediatrician in Georgia and spending time at home with her children, Dr. Jen […]

January 24, 2024
GO TO TOP